Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-11-02

Clinical Trial Update: Long Term Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating long-term efficacy and safety of fingolimod (FTY720) in de novo adult renal transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Fingolimod (fingolimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Renal Transplantation | Phase 3 | Status: COMPLETED